COG-AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse
- Title
- A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse
- Principal Investigator
- Meyer, Ashley
- Phase
- II
- Age Group
- Both
- Applicable Disease Sites
- Leukemia
- Participating Institutions
- Mary Babb Randolph Cancer Center
- West Virginia University
- Contacts
- Carla Corbin, RN, BSN
- Nurse Clinician
- Phone: +1 304-293-1217
- Email: ccorbin@hsc.wvu.edu
- Christy Glass, MSN
- APRN
- Phone: +1 304-598-4835
- Email: christy.glass@hsc.wvu.edu
- Ashley Kitzmiller, RN
- Nurse Coordinator
- Phone: +1 304-293-1217
- Email: ashley.tomasello@wvumedicine.org
- Lily Kastelic, BS
- Data Analyst
- Email: lily.kastelic@hsc.wvu.edu